Drugs News and Research

RSS

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Alexion Pharmaceuticals, Inc. joins the European Organization for Rare Diseases, the National Organization for Rare Disorders and families, governments, companies and medical communities around the world in observing the fourth annual Rare Disease Day today.

28 Feb 2011

Immunitor to present latest results from imm01 trial in tuberculosis patients at African conference

Immune Network Ltd. advises that Immunitor will present latest results from its imm01 clinical trial in tuberculosis patients in Abuja, Nigeria at the 18th Union TB and Lung Diseases Conference of the African Region, 2nd to 5th March, 2011.

28 Feb 2011

AARP commends lawmakers for their opposition to health care nullification bill

Averting a potentially disastrous piece of legislation, a majority of Idaho Senators on the State Affairs Committee took a bold stand and voted down a measure to "nullify" the federal health care law in Idaho.

28 Feb 2011

Researchers to examine thrombolysis for treatment of DVT in leg

Blood clots in the leg occur commonly. In one-half of the cases, the blood clot will break loose and travel through the bloodstream to the lungs - which may be life-threatening.

28 Feb 2011

Medunik to introduce novel orphan drugs to Canadians with rare diseases

Éric Gervais, Executive Vice-President of Medunik Canada, is proud to announce the Management Team of this recently created company. Medunik Canada is a Quebec pharmaceutical company with 60 employees and one unique mission - bring novel orphan drugs to Canadians with rare diseases.

28 Feb 2011

Almac's new North American Headquarters launches schedule I-V controlled capabilities

Packaging, storage and distribution of schedule I-V controlled substances is now a fully functional capability of Almac's new North American Headquarters in Souderton, PA. As the phased transition nears its end, the portfolio of services and capacity offered to customers continues to grow as a result of the $120 million investment.

28 Feb 2011

Despite FDA action, Deston still believes Auralgan as a safe and effective drug product

Deston Therapeutics LLC announced today that it is currently exploring its options to respond to a recent seizure of its Auralgan Otic Solution by the Federal Government and that it still believes that Auralgan is a safe and effective drug product.

28 Feb 2011

New horse stem cell discovery aids in preclinical model development for human degenerative diseases

In a world first, pluripotent stem cells have been generated from horses by a team of researchers led by Dr. Andras Nagy at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital and Dr. Lawrence Smith at the University of Montreal's Faculty of Veterinary Science.

28 Feb 2011

New research may shed light on how HIV virus reactivates from latency

New research enhances the current knowledge of how human immunodeficiency virus type-1, which causes AIDS, controls the cell cycle of cells that it infects. The new findings may shed light on how the virus reactivates after entering a dormant state, called latency.

28 Feb 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Study: Storytelling program improves communication skills, positive affect in persons with dementia

Nearly 16 million Americans will be diagnosed with Alzheimer's disease or another type of dementia by 2050, according to the Alzheimer's Association. Symptoms include mood and behavior changes, disorientation, memory loss and difficulty walking and speaking.

28 Feb 2011

AHRQ: $52.2 billion spent on prescription drugs for treatment of metabolic conditions during 2008

Insurers and consumers spent $52.2 billion on prescription drugs in 2008 for outpatient treatment of metabolic conditions such as diabetes and elevated cholesterol, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

28 Feb 2011

Scripps Health offers genetic testing to patients with Hepatitis C

Scripps Health is one of the first health systems in the United States to offer genetic testing as part of its care for hepatitis C patients planning to undergo drug treatment.

28 Feb 2011

Researchers identify gene behind self-healing skin cancer

Cancer Research UK scientists have discovered the gene behind a rare skin cancer which grows rapidly for a few weeks before healing spontaneously, according to research published in Nature Genetics.

28 Feb 2011

Scientists discover killer protein that protects against development of cancer

Scientists at Trinity College Dublin have made an important discovery concerning how fledgling cancer cells self-destruct, which has the potential of impacting on future cancer therapies.

27 Feb 2011

Phase III trial results: Erlotinib has comparable efficacy to chemotherapy with better tolerability against lung cancer

The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show.

27 Feb 2011

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that encouraging preliminary results of a Phase 2 trial of ganetespib as a single agent in non-small cell lung cancer were presented at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

27 Feb 2011

Avastin debate spills over until June FDA hearing

The U.S. Food and Drug Administration have granted Roche a hearing in June to defend the cancer treatment Avastin. The hearing would examine the effectiveness of the drug in breast cancer.

27 Feb 2011

U.S.-Chile collaborate to study new long-acting local anesthetic derived from algae

A U.S.-Chile collaboration is bringing surgical patients closer to having a long-acting local anesthetic. In a randomized, double-blind trial, patients given neosaxitoxin, a new local anesthetic derived from algae, had significantly less postoperative pain and recovered about two days sooner than those given the commonly used local anesthetic bupivacaine.

25 Feb 2011

Discovery highlights unexpected role for killer protein in 'autophagy'

Scientists at Trinity College Dublin have made an important discovery concerning how fledgling cancer cells self-destruct, which has the potential of impacting on future cancer therapies. The Trinity research group, led by Smurfit Professor of Medical Genetics, Professor Seamus Martin and funded by Science Foundation Ireland, has just published their findings in the internationally renowned journal, Molecular Cell.

25 Feb 2011

Drugs News and Research

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Immunitor to present latest results from imm01 trial in tuberculosis patients at African conference

AARP commends lawmakers for their opposition to health care nullification bill

Researchers to examine thrombolysis for treatment of DVT in leg

Medunik to introduce novel orphan drugs to Canadians with rare diseases

Almac's new North American Headquarters launches schedule I-V controlled capabilities

Despite FDA action, Deston still believes Auralgan as a safe and effective drug product

New horse stem cell discovery aids in preclinical model development for human degenerative diseases

New research may shed light on how HIV virus reactivates from latency

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

Study: Storytelling program improves communication skills, positive affect in persons with dementia

AHRQ: $52.2 billion spent on prescription drugs for treatment of metabolic conditions during 2008

Scripps Health offers genetic testing to patients with Hepatitis C

Researchers identify gene behind self-healing skin cancer

Scientists discover killer protein that protects against development of cancer

Phase III trial results: Erlotinib has comparable efficacy to chemotherapy with better tolerability against lung cancer

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Avastin debate spills over until June FDA hearing

U.S.-Chile collaborate to study new long-acting local anesthetic derived from algae

Discovery highlights unexpected role for killer protein in 'autophagy'

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News